Cover Image
市場調查報告書

Grupo Ferrer Internacional, S.A.的產品平台分析

Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320918
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
Grupo Ferrer Internacional, S.A.的產品平台分析 Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 38 Pages
簡介

Grupo Ferrer Internacional, S.A.是製藥企業,除了從事心血管系統、中樞神經系統、腫瘤、皮膚疾病、消化器官系統、肌肉骨骼系統、疼痛管理、小兒科、呼吸系統等領域之醫藥品的製造銷售外,更提供診斷服務、疫苗接種、學名藥、API、食品、食品添加物、醫藥產品、化妝品、養生保健產品用原料等廣泛的業務。

本報告提供Grupo Ferrer Internacional, S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Grupo Ferrer Internacional, S.A.的基本資料

  • Grupo Ferrer Internacional, S.A.概要
  • 主要資訊
  • 企業資料

Grupo Ferrer Internacional, S.A.:R&D概要

  • 主要的治療範圍

Grupo Ferrer Internacional, S.A.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Grupo Ferrer Internacional, S.A.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Grupo Ferrer Internacional, S.A.:藥物簡介

  • ozenoxacin
  • arasertaconazole
  • lorediplon
  • FIB-111
  • FIB-112
  • FIB-114
  • FIB-116
  • FIB-117
  • Drugs for Bacterial Infections
  • Drugs to Target Orexin Receptor for Narcolepsy and Sleep Disorders
  • Malaria Program

Grupo Ferrer Internacional, S.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Grupo Ferrer Internacional, S.A.:最新的開發平台資訊

Grupo Ferrer Internacional, S.A.:開發暫停中的計劃

Grupo Ferrer Internacional, S.A.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

目錄
Product Code: GMDHC06626CDB

Summary

Global Markets Direct's, 'Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014', provides an overview of the Grupo Ferrer Internacional, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grupo Ferrer Internacional, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Grupo Ferrer Internacional, S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Grupo Ferrer Internacional, S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Grupo Ferrer Internacional, S.A.'s pipeline products

Reasons to buy

  • Evaluate Grupo Ferrer Internacional, S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Grupo Ferrer Internacional, S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Grupo Ferrer Internacional, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Grupo Ferrer Internacional, S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grupo Ferrer Internacional, S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Grupo Ferrer Internacional, S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Grupo Ferrer Internacional, S.A. Snapshot
    • Grupo Ferrer Internacional, S.A. Overview
    • Key Information
    • Key Facts
  • Grupo Ferrer Internacional, S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Grupo Ferrer Internacional, S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Grupo Ferrer Internacional, S.A. - Pipeline Products Glance
    • Grupo Ferrer Internacional, S.A. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Grupo Ferrer Internacional, S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Grupo Ferrer Internacional, S.A. - Drug Profiles
    • ozenoxacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • arasertaconazole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lorediplon
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIB-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIB-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIB-114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIB-116
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FIB-117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Target Orexin Receptor for Narcolepsy and Sleep Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Malaria Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Grupo Ferrer Internacional, S.A. - Pipeline Analysis
    • Grupo Ferrer Internacional, S.A. - Pipeline Products by Target
    • Grupo Ferrer Internacional, S.A. - Pipeline Products by Route of Administration
    • Grupo Ferrer Internacional, S.A. - Pipeline Products by Molecule Type
    • Grupo Ferrer Internacional, S.A. - Pipeline Products by Mechanism of Action
  • Grupo Ferrer Internacional, S.A. - Recent Pipeline Updates
  • Grupo Ferrer Internacional, S.A. - Dormant Projects
  • Grupo Ferrer Internacional, S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Grupo Ferrer Internacional, S.A., Key Information
  • Grupo Ferrer Internacional, S.A., Key Facts
  • Grupo Ferrer Internacional, S.A. - Pipeline by Indication, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Stage of Development, 2014
  • Grupo Ferrer Internacional, S.A. - Monotherapy Products in Pipeline, 2014
  • Grupo Ferrer Internacional, S.A. - Partnered Products in Pipeline, 2014
  • Grupo Ferrer Internacional, S.A. - Partnered Products/ Combination Treatment Modalities, 2014
  • Grupo Ferrer Internacional, S.A. - Phase III, 2014
  • Grupo Ferrer Internacional, S.A. - Phase II, 2014
  • Grupo Ferrer Internacional, S.A. - Discovery, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Target, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Route of Administration, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Molecule Type, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline Products by Mechanism of Action, 2014
  • Grupo Ferrer Internacional, S.A. - Recent Pipeline Updates, 2014
  • Grupo Ferrer Internacional, S.A. - Dormant Developmental Projects,2014
  • Grupo Ferrer Internacional, S.A., Other Locations
  • Grupo Ferrer Internacional, S.A., Subsidiaries

List of Figures

  • Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Indication, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Stage of Development, 2014
  • Grupo Ferrer Internacional, S.A. - Monotherapy Products in Pipeline, 2014
  • Grupo Ferrer Internacional, S.A. - Partnered Products in Pipeline, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Target, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Route of Administration, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Molecule Type, 2014
  • Grupo Ferrer Internacional, S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top